BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Topline results on the horizon for SynAct Pharma

2026-02-20 08:40:00

SynAct Pharma’s 2025 year-end report highlights a year of clinical execution and strategic expansion. With recruitment now complete for the phase IIb ADVANCE study in rheumatoid arthritis and the RESPIRE trial underway, the company is approaching transformative clinical readouts for resomelagon. BioStock contacted CEO Jeppe Øvlesen for a comment.

Read the full interview at biostock.se:

Topline results on the horizon for SynAct Pharma

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Vem äger bolaget?

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden